Recurrent Uterine Corpus Carcinoma Clinical Trial
Official title:
A Phase II Trial of ZD 1839 (IRESSA) (NSC #715055) in the Treatment of Persistent or Recurrent Endometrial Carcinoma
Phase II trial to study the effectiveness of gefitinib in treating patients who have persistent or recurrent endometrial cancer. Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of endometrial cancer.
OBJECTIVES:
I. Determine the 6-month progression-free survival of patients with persistent or recurrent
endometrial carcinoma after receiving gefitinib.
II. Determine the nature and degree of toxicity of this drug in these patients. III.
Determine the progression-free and overall survival of patients treated with this drug.
IV. Determine the effects of this drug on the levels of epidermal growth factor receptors
(EGFR), c-ErbB2 (HER-2/neu) receptors, estrogen receptors (ER), and progesterone receptors
(PR) (both PR and PRB) in tumor specimens of these patients.
V. Determine if an association exists between the levels of EGFR, ER, PR, PRB, and HER-2/neu
serum concentrations of gefitinib, gefitinib activity, and soluble EGFR and clinical outcome
in patients treated with this drug.
VI. Determine the frequency of clinical response (partial and complete response) in patients
treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
annually thereafter.
PROJECTED ACCRUAL: A total of 22-60 patients will be accrued for this study within 2.5-6
years.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01010126 -
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
|
Phase 2 | |
| Completed |
NCT01642082 -
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT01208467 -
Prognostic Biomarkers in Patients With Endometrial Cancer
|
N/A | |
| Completed |
NCT01011933 -
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT00729586 -
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT01440998 -
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
|
Phase 1 | |
| Completed |
NCT00006089 -
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT01225887 -
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT00410553 -
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery
|
Phase 1 | |
| Active, not recruiting |
NCT02208375 -
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01970722 -
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
|
Phase 1 | |
| Completed |
NCT02996825 -
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
|
Phase 1 | |
| Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
| Completed |
NCT01307631 -
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02065687 -
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT01210222 -
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT01132820 -
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT00897442 -
Collecting Tumor Samples From Patients With Gynecological Tumors
|
N/A | |
| Completed |
NCT02657928 -
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT00888173 -
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 |